Cernostics is focused on delivering the next generation of cancer diagnostics & prognostics through a unique approach to tissue analysis.

Learn about our approach...

Barrett's Esophagus & Esophageal Cancer

Three million people in the U.S. have Barrett's Esophagus, a known precursor to esophageal cancer. Until now, identifying which patients are at greatest risk for esophageal cancer has been impossible. Cernostics is looking to change that… Learn how
View All News
New TissueCypher® Validation Study identifies high risk Barrett’s Esophagus patients who are 46x more likely to have cancer at time of biopsy... Read More
UPMC Partners with Cernostics to Pursue ‘Precision Medicine’... Read More
Cernostics Announces Scientific Presentations at DDW and ISPOR Meetings Demonstrating Clinical Validation and Cost-Effectiveness of New TissueCypher® Barrett's Esophagus Assay... Read More
10/18/2014 Vienna, Austria
UEG Week (United European Gastroenterology Week)
06/23/2014 San Diego, CA
BIO International Convention
05/03/2014 Chicago, IL
DDW (Digestive Disease Week)
01/13/2014 San Francisco, CA
JP Morgan Healthcare Conference
11/13/2013 Philadelphia, PA
PA BIO Life Sciences Future Meeting
Customer Service

Mon-Fri 9am-5pm (EST)